"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules are indicated for patients with pancreatic exocrine insufficiency as is often associated with:
DOSAGE AND ADMINISTRATION
Clinical experience should dictate initial starting dose. Doses should be taken during meals or snacks, not before or after. Do not take without food.
Adults and Children Over 6 Years Old
Usual initial starting dosage is two to four CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules per meal or snack.
Children Under 6 Years Old
The exact dosage of CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules should be selected based on clinical experience for this age group. Patients can be started on one to two capsules per meal or snack.
For cystic fibrosis patients, typical doses are 1,500 - 3,000 USP lipase units/kg/meal. Dosage should be adjusted according to the severity of the disease, control of steatorrhea and maintenance of good nutritional status. Doses in excess of 6,000 USP lipase units/kg/meal are not recommended.
Dose increases, if required, should occur with careful monitoring of body weight and stool fat content. When changing strengths of pancreatic enzyme products, care should be taken to maintain equivalent lipase units for each divided dosage.
It is important to ensure adequate hydration of patients at all times while taking pancreatic enzymes.
Where swallowing of capsules is difficult, the capsules may be carefully opened and the MINIMICROSPHERES added to a small amount of soft food, with a pH less than 5.5. The soft food should be swallowed immediately without chewing and followed with a glass of water or juice to insure swallowing.
CREON 5 MINIMICROSPHERES (Pancrelipase Delayed-release Capsules, USP) are available in a two-piece gelatin capsule (orange opaque top half, blue opaque bottom half) imprinted in white with "SOLVAY" and "1205". Each capsule contains tan-colored delayed-release MINIMICROSPHERES of pancrelipase supplied in bottles of:
CREON 5 (pancrelipase delayed-release minimicrospheres) Capsules must be stored at 25ºC (77ºF); excursions permitted to 15°-30°C (59°- 86°F). [See USP Controlled Room Temperature.] PROTECT FROM MOISTURE. DO NOT REFRIGERATE. Dispense in tight, light-resistant containers. For human consumption only.
Manufactured By: Solvay Pharmaceuticals GmbH, Hannover, Germany. Marketed by: Solvay Pharmaceuticals, Inc. Marietta, GA 30062. Rev Feb 2006. FDA Rev date: n/a
Last reviewed on RxList: 9/29/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Creon 5 Information
Creon 5 - User Reviews
Creon 5 User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.